Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0152W HIGH $83,600.00
Volume
48.17 K
Value Traded
413.15 K
Short % Float
3.1%
Days to Cover
3.1
+3.67%Week
-39.25%1 Month
-44.61%3 Month
-99.06%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.05 M
EPS (TTM)
-102.30
P/E Ratio
-
Ent. Value
5.30 M
Total Shares
4.47 M
Float Shares
4.42 M
Insiders
1.14%
Institutions
0.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
WOK Catalyst Timeline
Dated clinical, regulatory and corporate events for WORK Medical Technology Group LTD
Past FDA Catalysts and PDUFA Decisions
How WOK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
WORK Medical Technology Group LTD is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every WOK program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRT FINANCIAL LP10% Owner | Sell | -136,665 123,944 held | $3.87 | 06/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in WOK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in WOK for Q2 2026. | ||||
WOK Institutional Ownership Trends
WOK Short Interest
Shares sold short, counted twice a month.
3.1%
Short % of Float
of tradable shares sold short
136.8K
Shares Sold Short
+0.2% vs prior count
3.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
44.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WOK ranks across every disease it competes in
Competitive Position is a premium feature
See how WOK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWOK News
WOK▼ -40.8%on this news· ran to -64% by day 3
WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026
WORK Medical Technology Group LTD has announced a 1-for-100 reverse stock split effective June 18, 2026. This move aims to consolidate shares and potentially enhance the stock's market value. After the split, approximately 2.42 million Class A ordinary shares will be outstanding. The company continues to operate in the medical device sector with a diverse product range.
Read more →WOK▼ -15.7%on this news
WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference
WORK Medical Technology Group participated as a partner and exhibitor at the 2026 CBA-China Annual Conference, which took place from May 8 to 10 in Wuxi, Jiangsu Province. The conference brought together experts from the global biopharmaceutical sector to discuss key topics like AI applications in life sciences and global supply chain collaboration. WORK Medical utilized this opportunity to showcase its medical devices and strategic focus on AI-driven healthcare solutions. The company's engagement at the conference aligns with its strategy to enhance international partnerships and innovation efforts in the healthcare space.
Read more →WOKWORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy
WORK Medical Technology Group has established a U.S. subsidiary, Work Bio Technologies Ltd, to enhance its global expansion and long-term growth strategy. This subsidiary will serve as the primary operational platform in the U.S., improving supply chain management and customer engagement. CEO Mr. Wu Shuang emphasized the significance of this move for accelerating business development and strengthening international partnerships.
Read more →WOK▲ +206.3%on this news· ran to +420% by day 1
WORK Medical Collaborates with Novabioplus to Unlock Biological Data Value with AI, Advancing the “BioToken” Assetization Model
WORK Medical has partnered with Novabioplus to advance AI-driven healthcare solutions. This collaboration aims to integrate AI algorithms with extensive protein datasets to enhance the development of protein antibody therapeutics. The initiative includes four major projects focused on biomolecular design and aims to create 'BioTokens' for biological assets. This partnership marks a significant step in WORK Medical's evolution toward a digital ecosystem in life sciences.
Read more →WOK▲ +6.6%on this news
WORK Medical Deepens Web3.0 Strategic Layout: Co-authors Asset Tokenization Whitepaper
WORK Medical Technology Group LTD has been awarded a Vice President Unit certificate by the Hong Kong Web3.0 Standardization Association. The company is advancing its Web3.0 strategy through the release of an Asset Tokenization Whitepaper, which aims to establish standards for the integration of medical assets with blockchain technology. This initiative is part of a broader strategy to enhance digital infrastructure in healthcare.
Read more →WOKWORK MEDICAL TECHNOLOGY GROUP LTD (an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: WOK) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the ann
WORK Medical Technology Group Ltd is scheduled to hold its annual general meeting on February 25, 2026, in Hangzhou, China. Shareholders will have the option to attend in person or virtually via a live webcast. The meeting will address significant resolutions, including a proposed share capital increase and adjustments to the company's memorandum of association. Key director elections and a share consolidation will also be discussed.
Read more →WOKWORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026
WORK Medical Technology Group has signed a one-year exclusive distribution agreement with Shanghai Benke Medical to market its AI-Automated Blood Cell Morphology Analyzer in East China. The agreement sets a sales target of RMB 10 million for 2026, aiming to enhance market penetration. The Analyzer, recently approved as a Class II medical device, boasts high imaging speed and classification accuracy.
Read more →WOKWORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer
WORK Medical Technology Group's subsidiary has received manufacturing approval for its AI-automated blood cell morphology analyzer from the Hunan Provincial Medical Products Administration. This Class II medical device is designed to improve the efficiency and accuracy of blood cell analysis, supporting clinicians in diagnosing blood disorders. The device is expected to begin manufacturing in the first half of 2026, marking a significant advancement in the company's product offerings.
Read more →WOKWORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025
WORK Medical Technology Group LTD announced a 1-for-100 reverse stock split effective December 29, 2025, following approval from shareholders and the board. This action is primarily aimed at complying with Nasdaq Marketplace Rule 5550(a)(2) regarding minimum share price maintenance. The reverse stock split will not affect shareholders' percentage ownership, except for adjustments due to rounding up of fractional shares. The company's Class A and B ordinary shares will continue trading under the symbol WOK.
Read more →WOKWORK MEDICAL TECHNOLOGY GROUP LTD UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. dollars, except for otherwise noted) As of
Work Medical Technology Group Ltd has released its unaudited condensed consolidated balance sheets and income statements for the six months ending March 31, 2025. The company reported total assets of $34,713,064, a decrease from $36,250,563 in the prior reporting period. Significant issues highlighted include a net loss of $29,425 during this period and a notable decrease in cash and cash equivalents. Despite a marginal increase in current assets and maintaining substantial revenue from third parties, the overall financial outlook indicates challenges due to increasing liabilities and operational losses.
Read more →WOKWORK Medical Technology Group LTD’s Subsidiary Retains a US$114,000 Service Contract from GemPharmatech Corporation
WORK Medical Technology Group LTD's subsidiary, Neologics Bioscience Inc., has secured a $114,000 service contract with GemPharmatech Corporation. This agreement marks a significant step in WORK Medical's global expansion and diversification strategy, focusing on R&D execution. Neologics will provide various testing services, enhancing its collaboration with industry peers and supporting its growth trajectory.
Read more →WOKWORK Medical Technology Group LTD Announces US$1 Million Equity Investment in Neologics Bioscience
WORK Medical Technology Group LTD has announced a US$1 million equity investment in Neologics Bioscience, acquiring a 10% stake. This partnership aims to leverage Neologics' R&D capabilities alongside WORK Medical's operational strengths to foster innovation in medical technology. The investment will support Neologics' operations and market expansion.
Read more →WOKWORK MEDICAL TECHNOLOGY GROUP LTD (an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: WOK) NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the extr
WORK Medical Technology Group Ltd has scheduled an extraordinary general meeting for shareholders on November 7, 2025, at 9:30 a.m. Eastern Time. The meeting will allow shareholders to vote on several key resolutions, including a share consolidation and capital increase. Shareholders of record as of October 15, 2025, are entitled to attend and vote, either in person or virtually. The Board of Directors recommends a vote in favor of the proposed resolutions, highlighting a unified stance on the company's strategic direction.
Read more →WOKWORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective October 21, 2025
WORK Medical Technology Group LTD has announced a 1-for-100 reverse stock split effective October 21, 2025. This decision, approved by shareholders and the board, aims to comply with Nasdaq's minimum bid price requirements. The split will reduce the number of outstanding shares significantly while maintaining shareholder percentages, except for rounding adjustments.
Read more →WOKWORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from Nasdaq
WORK Medical Technology Group LTD has received a delisting determination letter from Nasdaq due to its Class A ordinary shares trading below $0.10 for ten consecutive days. The company has until October 16, 2025, to appeal this decision to avoid suspension of trading on October 20, 2025. The company is considering options to regain compliance, including a potential reverse share split.
Read more →WOKWORK Medical Technology Group LTD Granted Additional 180-Day Period to Regain Nasdaq Compliance
WORK Medical Technology Group LTD has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. This follows an initial notice indicating the company's stock had not met the necessary criteria. The company plans to address this issue, potentially through a reverse stock split, to avoid delisting.
Read more →WOKWORK Medical Technology Group LTD Announces Pricing of $2.9 Million Registered Direct Offering
WORK Medical Technology Group LTD has announced a registered direct offering of 38,999,334 Class A ordinary shares at $0.075 per share, aiming to raise approximately $2.9 million. The transaction is set to close around September 26, 2025, pending customary conditions. The offering is part of a shelf registration previously approved by the SEC.
Read more →WOKWORK Medical Technology Group LTD Partners with Hong Kong Web3.0 Standardization Association to Collaborate on Blockchain and RWA Innovations
WORK Medical Technology Group LTD has partnered with the Hong Kong Web3.0 Standardization Association to innovate in the Real-world Asset sector. This strategic cooperation aims to develop blockchain solutions and enhance industry standards. The partnership signifies WORK Medical's commitment to advancing technology and business models in the Web3.0 ecosystem.
Read more →WOKWORK Medical Technology Group LTD Partners with Wuxi Branch of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine to Develop AI-Applications in Healthcare
WORK Medical Technology Group LTD has partnered with the Wuxi Branch of Ruijin Hospital to develop AI applications in healthcare. This strategic cooperation aims to enhance hospital informatization and create a digital knowledge base for intelligent healthcare. The collaboration will leverage Xin Rui Hospital's clinical resources to advance AI-driven medical solutions, potentially transforming healthcare delivery in China.
Read more →About WORK Medical Technology Group LTD
BIOPHARMAWATCH ELITE PLUS
Trade the next WOK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime